Evoke Pharma Inc (NASDAQ:EVOK) has received a consensus rating of “Hold” from the ten ratings firms that are currently covering the stock. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $8.20.

A number of brokerages have recently commented on EVOK. Ascendiant Capital Markets lifted their price target on shares of Evoke Pharma from $5.00 to $6.00 and gave the stock an “in-line” rating in a report on Thursday, March 16th. Rodman & Renshaw reiterated a “buy” rating and set a $9.00 price target (up from $6.00) on shares of Evoke Pharma in a report on Thursday, March 16th. HC Wainwright set a $9.00 price target on shares of Evoke Pharma and gave the stock a “buy” rating in a report on Thursday, March 16th. Zacks Investment Research downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a report on Monday, March 20th. Finally, FBR & Co reiterated a “positive” rating and set a $9.00 price target on shares of Evoke Pharma in a report on Tuesday, January 31st.

Evoke Pharma (NASDAQ:EVOK) traded down 3.00% during mid-day trading on Monday, hitting $2.59. 280,653 shares of the stock were exchanged. The company has a 50-day moving average price of $3.03 and a 200-day moving average price of $2.37. The company’s market cap is $31.87 million. Evoke Pharma has a one year low of $1.35 and a one year high of $11.11.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Wednesday, March 15th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.07. During the same quarter in the previous year, the company earned ($0.37) EPS. Analysts forecast that Evoke Pharma will post ($0.67) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/evoke-pharma-inc-evok-receives-8-20-consensus-price-target-from-analysts/1205692.html.

In related news, Director Kenneth J. Widder bought 450,000 shares of the stock in a transaction that occurred on Wednesday, February 22nd. The stock was purchased at an average cost of $2.90 per share, for a total transaction of $1,305,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 30.50% of the stock is currently owned by insiders.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

5 Day Chart for NASDAQ:EVOK

Receive News & Ratings for Evoke Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.